Vancomycin-Associated Nephrotoxicity

Completed

• Conditions: Nephrotoxicity

• Registration Number: NCT01216540
• Lead Sponsor: University at Buffalo

Brief Summary

The primary goal of this study is to determine if there is an association between greater exposure to vancomycin and the development of nephrotoxicity. The secondary goal is to estimate the costs to the hospital associated with these nephrotoxic events.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-10-06
• Study First Submitted QC: 2010-10-06
• Study First Posted: 2010-10-07
• Study Start: 2010-11
• Primary Completion: 2011-04
• Study Completion: 2011-04
• Status Verified: 2022-09
• Last Update Submitted: 2022-09-30
• Last Update Posted: 2022-10-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 398

Inclusion Criteria

• 18 years or older at time of hospital admission
• Had an absolute neutrophil count of ≥ 1000 cells/mm^3
• Received > 48 hours of intravenous vancomycin therapy
• Had one or more vancomycin trough levels reported within the 96 hours after therapy initiation
• Had a baseline serum creatinine level of < 2.0 mg/dL and baseline creatinine clearance level of ≥ 30 mL/min

Exclusion Criteria

• Previous diagnosis of cystic fibrosis

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time to nephrotoxicity	within 72 hours post completion of vancomycin therapy

Secondary Outcome Measures

Name	Time	Method
Hospital costs	until discharge
Length of stay	until discharge

Trial Locations

Locations (1)

University of Rochester Medical Center; 🇺🇸 Rochester, New York, United States